Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Pediatric rheumatology

Clinical trials

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Browse the hub

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Visit the hub

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Visit the hub

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Visit the conference hub

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Read the article

Telemedicine in rheumatology

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Browse the hub

Get ready for ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Visit the conference hub

01-07-2018 | Juvenile idiopathic arthritis | Article

Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial

Bharucha KN et al. J Rheumatol 2018. doi: 10.3899/jrheum.170326

26-06-2018 | Juvenile idiopathic arthritis | Article

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis

Lovell DJ et al. Pediatr Rheumatol 2018; 16: 41. doi: 10.1186/s12969-018-0260-y

12-05-2018 | Systemic lupus erythematosus | Article

Nutritional intervention in patients with juvenile systemic lupus erythematosus: Protective effect against the increase in fat mass

Abad TO et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4031-3

13-04-2018 | Juvenile idiopathic arthritis | Article

Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial

Opoka-Winiarska V et al. Clin Rheumatol 2018; Advance online publication. doi: 10.1007/s10067-018-4071-9

27-02-2018 | Juvenile idiopathic arthritis | Article

A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)

Ramanan AV et al. BMC Rheumatol 2018; 2: 4. doi: 10.1186/s41927-018-0010-2

24-01-2018 | Pathogenesis | Review | Article

Moving towards a molecular taxonomy of autoimmune rheumatic diseases

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220


More on pediatric rheumatology


« Back to main page | Juvenile idiopathic arthritis | Clinical trials | Comorbidities | Diagnosis and screening | Epidemiology | Medications | Non-pharmacologic treatment | Pathophysiology | Quality of life


Image Credits